BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
Our client retention is unparalleled in the industry because we are much more than just the provider of quality diagnostics. We have grown primarily as a result of our differentiating business model which is both physician-centric – providing superior service and support – and clinically relevant – providing innovative and disruptive technology to improve patient outcomes. What makes us different from other labs is the added value we bring through personal attention and professional support and the effort we make to understand our clients’ needs. Our success comes from helping clinicians deliver premium services to the patients in their care – through a full menu of cost–conscious testing options and cutting edge technologies with clinically–relevant results, all in a medically and fiscally responsible manner.
In addition, BioReference has pioneered the development of business solutions for our clients, providing data and analytics to help them operate at their fullest potential.
The Laboratory services multiple markets through several specialized business units, each with its own dedicated sales team and highly-trained support personnel. These include women’s health, oncology, genetics and a lab division focused exclusively on the nation’s expanding Spanish-speaking populations.
Clinical Diagnostics, Oncology, Women's Health, Genetic Testing
Dr Marc GrodmanMD
Mr Joseph Donahue
Professor Robert DaberPhD
The Biotech City is a biopharmaceutical and life sciences cluster in Greater Montreal, located near an international airport and subway network. The life sciences sector in Laval is comprised of more than 90 companies and institutions, many of which are leaders in Canada’s science economy and which employ some 5,000 people within a four-kilometre radius. The hub is made up of companies specializing in biotechnology, pharmaceuticals, medical equipment, CROs and information technology. The Biotech City is also home to an integrated life sciences technology park built around two research institutes, a business incubator, laboratory facilities and development lots.
The Biotech City helps drive the life sciences industry
• Promotes networking among businesses, investors, research institutes and government agencies
• Organizes and participates in biopharmaceutical sector events
• Represents the life sciences sector on a local and international level
The Biotech City will support you in your implementation project
• Assistance in finding lots, sites and facilities
• Guidance and support through all administrative steps
• International mobility expertise
Mr Jean-Marc JuteauDirector
Boehringer Ingelheim Pharmaceuticals Inc.
Mr Cyrille KuhnExecutive Director - Research Beyond Borders
Boler Biotech Consulting
Boler Biotech Consulting is a Boston based biotechnology investing and consulting firm focused on early stage, private, and public Life Science companies.
We provide strategic research and analysis for investors and clients with early-stage biotechnology companies. This includes scientific assessment, due diligence, and analysis of market potential of new technologies and therapies.
We pride ourselves on identifying and partnering with startup companies and investors who successfully commercialize technologies most likely to improve the lives of patients and yield robust returns for investors.
Mr William JohnsonManaging Partner
Boston Biotech Clinical Researc, LLC
Simplifying Clinical Research
Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research.
BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research.
BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfil their product development.
The innovative approach offered by BBCR facilitates:
• Strategic clinical plan that, accelerate value creation from the earliest phase of clinical trials
• Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators
• Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes
• Design-focused trials that facilitate patients’ recruitment and retention, and cost-effective clinical research
Dr Fratazzi CandidaPresident
Boston Biotech Clinical Research
Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research. BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research. BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfill their product development strategies.
The innovative approach offered by BBCR facilitates:
- Strategic clinical plans that, accelerate value creation from the earliest phase of clinical trials
- Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators
- Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes
- Design-focused trials that facilitate patient recruitment and retention, and cost-effective clinical research
Dr cecile Levylead contact in management of autism team , scientific partnerships
Boston Harbor Angels
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of our assets in high-growth, early-stage companies. Since 2004 we have made investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation, etc. We believe we contribute more than money to the companies we fund and welcome the opportunity to work with entrepreneurs who are open to taking advice, yet have the smarts and determination to make their company successful.
Our focus is on early-stage companies, usually looking to raise $250K to $1.5M, where we can fund a portion of the round and syndicate the deal with other angel groups or early-stage venture funds. The company should be close to the commercialization stage and have a clear and defensible competitive advantage. We are looking for capital-efficient businesses that can reach profitability with less than $5M of equity investment and provide at least a tenfold return on the investment within five years.
BHA does not invest as a fund—each of our members makes his or her individual investment decision—but we collaborate in due diligence. We are open to any opportunities that can make a strong business case and can take the position of a lead investor if one of us has strong expertise within our group.
BHA receives 20-30 business summaries each month, out of which we select eight companies to make a personal presentation to our screening committee. The screening committee consists of volunteers from the group. The presentations are 10 minutes long, followed by 30-minute interactive discussion on the business opportunity. We provide our feedback on the strategy, tactics, presentation style, etc. on the spot. Four of the companies are invited to present to the whole group, so as to get members interested. After that, we decide to undertake due diligence concerning the companies before making an investment.
Boston Harbor Angels was founded by Mic Williams (president) in February 2004. Day-to-day operations are managed by Boris Batchvarov (managing director).